Century Therapeutics revenue was $114.90M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q1 2025) ending on Mar 31, 2025 was $109.2M, up 2,516% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IPSC annual revenue was $6.6M, with 194.8% growth year-over-year.
IPSC past revenue growth
How has IPSC's revenue growth performed historically?
Century Therapeutics (NASDAQ: IPSC) reported Q1 2025 revenue of $109.16 million up 12,667.72% year over year. In the same quarter last year, Century Therapeutics's revenue was $855.00 thousand.
What was Century Therapeutics's revenue in 2024?
Century Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $6.59 million, a 194.81% increase year over year.
How much does Century Therapeutics make in a day?
Based on Century Therapeutics annual revenue for the past four years, IPSC makes an average of $9,604.79 per day.
What was Century Therapeutics's annual revenue growth in the past year?
As of Q2 2025, Century Therapeutics's revenue has grown 8,286.79% year over year. This is 6,925.64 percentage points higher than the US Biotechnology industry revenue growth rate of 1,361.15%. Century Therapeutics's revenue in the past year totaled $114.90 million.
How much does Century Therapeutics make in a year?
Century Therapeutics's revenue by year for the past four years is:
Century Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $6.59 million, a 194.81% increase year over year.
Century Therapeutics's annual revenue for Dec 31, 2023 was $2.24 million, a 57.01% decrease from 2022.
Century Therapeutics's annual revenue for 2022 was $5.20 million, a Infinity% increase from 2021.
Century Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.